Cat. No.: 506 017
Amount: 100 µg
Price:
$415.00
|
|
|
| Cat. No. 506 017 |
100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use. Antibodies should be stored at +4°C when still lyophilized. Do not freeze! |
| Applications |
IP: not tested yet ICC: not tested yet IHC: not tested yet IHC-P: 1 : 1:1000 up to 1 : 1:2000 (see remarks) |
| Clone | SY-118C4 |
| Subtype | IgG2a (κ light chain) |
| Immunogen | Synthetic peptide corresponding to AA 239 to 252 from human TMEM106B (UniProt Id: Q9NUM4) |
| Epitop |
AA 239 to 252 from human TMEM106B (UniProt Id: Q9NUM4) |
| Reactivity |
Reacts with: human (Q9NUM4), mouse (Q80X71). Other species not tested yet. |
| Specificity | K.O. validated |
| Remarks |
WB: This antibody shows an additional unspecific band at 70kD. |
| Data sheet | 506_017.pdf |
|
|
TMEM106B or Transmembrane protein 106B is a lysosomal type II transmembrane protein which has been identified by a genome-wide association study as a potential risk factor for a neurodegenerative disorder called frontotemporal lobar degeneration (FTLD)(1). The C-terminal luminal domain of TMEM106B undergoes a proteolytic cleavage that forms sarkosyl-insoluble amyloid-like fibrils (residues 120-254) in human brains (2). TMEM106B is ubiquitously expressed, but the function of TMEM106B is almost unknown. TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry (3).